FLAMBOU

Human Organ Transplant System (H.O.T.S.) | Executive White Paper

The Crisis in Organ Transplantation

The U.S. organ transplant system is deeply fragmented, heavily reliant on outdated infrastructure, and struggling with widespread inefficiencies. While over **100,000 patients** wait for life-saving matches, approximately **20% of organs** from deceased U.S. donors go unused annually. The antiquated technology employed by legacy contractors introduces significant geographic inequities in organ allocation and costs Medicare roughly **$55 billion** annually. The patient journey remains precarious; successful organ matches trigger a high-pressure logistical cascade where a patient has just four hours to reach the operating room, followed by a lifetime of expensive treatment regimens for organ rejection.

100,000+	20%	$55 Billion
PATIENTS ON WAITLIST	UNUSED DONATED ORGANS	MEDICARE EXPENDITURE

The Market Catalyst

We are operating amidst a once-in-a-decade structural reset of U.S. organ transplant logistics and governance. A perfect storm of federal intervention and regulatory pressure has opened the market. The government has mandated the replacement of legacy systems, initiating a **$440 million** federal shift to dismantle archaic infrastructure. The broader transplantation market, currently valued at over $15 billion, is projected to double to $30 billion by the early 2030s.

The Flambou Solution: H.O.T.S.

Flambou, developed by Infiniti Global, is an AI-powered intelligence solution designed to streamline organ transplant logistics, coordination, and tracking. By targeting three core markets—Medical Industries (OPOs, OPTNs, Hospitals), Government (SBA 8(a), HRSA), and Direct-to-Consumer—Flambou provides a modern, 360-degree approach to patient communication and ecosystem efficiency.

- **Technological Superiority:** Unlike legacy systems suffering from deep institutional technical debt, Flambou leverages a cloud-native, multi-vendor platform powered by advanced AI and Machine Learning.
- **Clinical Decision Support:** The platform delivers real-time data analysis to prevent clinical errors, improve documentation accuracy, and actively reduce the rate of organ non-use.
- **User-Centric Benefits:** Designed to increase access to life-saving organs, reduce the risk of rejection, and promote shorter hospital stays through personalized post-transplant care.

Business Model & Strategic Vision

Flambou captures value through a multi-tiered revenue model encompassing onboarding fees, annual licenses, patient monitoring fees, and global donor data service contracts. With a Total Addressable Market (TAM) of $15 billion, Flambou is aggressively targeting a $150 million Serviceable Obtainable Market (SOM), aiming for a 3% market share in the U.S.

Currently raising **$5 million** to secure a 24-month runway, Flambou projects revenues to scale rapidly, targeting $6.5 million ARR by 2029 and $90 million by 2032. Initial traction includes SBA 8(a) HRSA engagement, active pilot conversations with OPOs and transplant centers, and established relationships across the OPTN network. Our ultimate humanitarian goal is to drive a 10% increase in productivity to sustainably reduce OPTN wait times.

Expert Leadership: Built by Doctors, For Doctors

Flambou's competitive edge is deeply rooted in personal experience and clinical insight. Led by CEO/Founder Michael Thomas—who brings 15 years of federal compliance and project management experience, alongside his personal journey as a kidney transplant candidate—the team is reinforced by world-class medical advisors including Dr. Nicole Ali, Dr. Sherla Sealey, and Dr. Danielle Greene. Together, they possess the necessary deep transplant and regulatory DNA to execute this transformative vision.

Presented by Infiniti Global | Michael Thomas, CEO | michael.thomas@flambou.co | 404-720-3937 | www.flambou.co